💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Unichem Laboratories Limited is an India-based international, integrated, specialty pharmaceutical company. The Company is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. It…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent business, reasonably priced — but flagged on governance.
Unichem Laboratories is scored on the pharma / healthcare framework. It keeps a healthy 11.2% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.01×) — worth a closer look. It throws off free cash worth 5.5% of its market value — a strong free-cash yield.
Book value has grown 4%/yr. Return on equity is a weak 4.3%. In the latest quarter profit grew 280% versus the prior quarter.
At 14× earnings, the stock sits at the 21st percentile of its own 1.6-year range — the cheap end of where it has historically traded. Today's price asks for only ~-0%/yr growth over a decade — undemanding expectations. The forensic screen raises a red flag: Only ₹-0.79 of cash per ₹1 profit over 4 years — earnings not converting to cash.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 10.45 | — | — |
| P/B | 1.27 | 4.11 | better |
| EV/EBITDA | 7.03 | 19.15 | better |
| ROE | 4.27 | — | — |
| ROCE | 5.51 | 6.87 | worse |
| ROA | 8.67 | — | — |
| Quick Ratio | 1.38 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 18% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
2 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a +84% swing — check if it's a one-off or structural.
Operating margin has expanded from -13% to 13% — the business is keeping more of each rupee earned.
ROE at 9% — modest; the capital isn't working hard. Capital efficiency improving — ROE up 18pp across the window.
EPS has grown every year — each share earns more than the last, consistently. 84% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
2 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Cash conversion at 0.0× PAT — reported profit isn't translating into cash, raising earnings quality questions. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 8% sequentially — momentum is building. Run-rate stepping up — recent quarters average 10% above earlier ones.
1 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 280% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (-2% → 6%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 1.6y median.
Promoters hold 70.2% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.